Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis
-
Abstract Number: 1478
Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
-
Abstract Number: 1479
Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data
-
Abstract Number: 1480
Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
-
Abstract Number: 1481
Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions
-
Abstract Number: 1483
Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase
-
Abstract Number: 1484
Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
-
Abstract Number: 1485
Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
-
Abstract Number: 1487
A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy
-
Abstract Number: 1488
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
-
Abstract Number: 1489
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
-
Abstract Number: 1490
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
-
Abstract Number: 1491
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
-
Abstract Number: 1492
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
-
Abstract Number: 1493
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
-
Abstract Number: 1494
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
-
Abstract Number: 1495
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
-
Abstract Number: 1496
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
-
Abstract Number: 1497
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
-
Abstract Number: 1498
ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
-
Abstract Number: 1499
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
-
Abstract Number: 1500
Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
-
Abstract Number: 1501
Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers
-
Abstract Number: 1502
A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis
-
Abstract Number: 1503
Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501
-
Abstract Number: 1504
Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
-
Abstract Number: 1505
The Biosimilar Landscape: A Systematic Review of Its Current Status
-
Abstract Number: 1506
Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico
-
Abstract Number: 1507
Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada
-
Abstract Number: 1508
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
-
Abstract Number: 1510
Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy
-
Abstract Number: 1511
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
-
Abstract Number: 1512
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
-
Abstract Number: 1513
Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
-
Abstract Number: 1514
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
-
Abstract Number: 1515
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
-
Abstract Number: 1516
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
-
Abstract Number: 1517
Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
-
Abstract Number: 1518
Disentangling the Effects of Tocilizumab on Neutrophil Survival and Function
-
Abstract Number: 1519
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
-
Abstract Number: 1520
Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial
-
Abstract Number: 1521
Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis
-
Abstract Number: 1523
Follow-up Data on the Rheumatoid Arthritis Comparison of Active Therapies Trial: Observational Cohort
-
Abstract Number: 1524
Rituximab Done! What’s Next in RA?
-
Abstract Number: 1525
Cumulative Clinical  Response in  Rheumatoid Arthritis Patients with  Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice Â
-
Abstract Number: 1526
Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year DataÂ
-
Abstract Number: 1527
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
-
Abstract Number: 1528
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
-
Abstract Number: 1529
Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
-
Abstract Number: 1530
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis
-
Abstract Number: 1531
CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry
-
Abstract Number: 1532
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
-
Abstract Number: 1533
Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
-
Abstract Number: 1534
Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden
-
Abstract Number: 1535
Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry
-
Abstract Number: 1536
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
-
Abstract Number: 1538
Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for All Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used
-
Abstract Number: 1539
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab